Home/Filings/4/0001127602-18-010088
4//SEC Filing

McKenzie Paul 4

Accession 0001127602-18-010088

CIK 0000875045other

Filed

Mar 4, 7:00 PM ET

Accepted

Mar 5, 4:41 PM ET

Size

12.4 KB

Accession

0001127602-18-010088

Insider Transaction Report

Form 4
Period: 2018-03-01
McKenzie Paul
EVP Pharmaceutical Oper & Tech
Transactions
  • Tax Payment

    Common Stock

    2018-03-01$282.35/sh405$114,3524,006.819 total
  • Exercise/Conversion

    Common Stock

    2018-03-01+5324,538.819 total
  • Exercise/Conversion

    Restricted Stock Unit

    2018-03-015321,160 total
    Exercise: $0.00Exp: 2019-03-01Common Stock (532 underlying)
  • Other

    Restricted Stock Unit

    2018-03-01312848 total
    Exercise: $0.00Exp: 2019-03-01Common Stock (312 underlying)
  • Tax Payment

    Common Stock

    2018-03-01$282.35/sh237$66,9174,301.819 total
Footnotes (2)
  • [F1]The number of RSUs reported represents the maximum possible number of shares that are eligible for vesting, which is 200% of the number of shares at target payout. One-third of these RSUs are eligible to vest on each of the first three anniversaries of the grant date. The actual number of shares that will vest on each vesting date will be determined by comparing the price of Biogen common stock on such vesting date to the price on the grant date (i.e., number of vested shares = number of shares at target payout times [the 30-day average closing stock price ending on the vesting date divided by the 30-day average closing stock price on the grant date]).
  • [F2]This represents the difference between the maximum possible number of shares that were eligible for vesting and the actual number that vested.

Issuer

BIOGEN INC.

CIK 0000875045

Entity typeother

Related Parties

1
  • filerCIK 0001677903

Filing Metadata

Form type
4
Filed
Mar 4, 7:00 PM ET
Accepted
Mar 5, 4:41 PM ET
Size
12.4 KB